ArticleFrontiers in cellular and infection microbiology2025
Virucidal and cytotoxic properties of a natural honeybee hives-derived formulation suspended with marine plasma.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Emerging viral pathogens continue to pose serious threats to global health, prompting the search for novel antiviral agents derived from natural sources. Bee-derived products, particularly those enriched with lysozyme, have shown promising antimicrobial properties. This study aimed to evaluate the virucidal and cytotoxic properties of a new formulation combining extract from bee brood caps (EBBC) and enhanced marine plasma as a potential broad-spectrum antiviral agent. Methods: The chemical composition of EBBC was characterized by gas chromatography-mass spectrometry (GC-MS) and lysozyme activity assays. Cytotoxicity was assessed using the sulforhodamine B (SRB) assay on normal epithelial (CCD841) and fibroblast (NHDF) cell lines. Virucidal activity was tested according to European (PN-EN 14476+A2:2019-08) and ISO (ISO 18184) standards. Additionally, the effect of EBBC on viral entry was analyzed using fluorescence microscopy. Results: EBBC demonstrated potent virucidal activity, achieving ≥99.99% efficacy at concentrations as low as 0.01% and maintaining full effectiveness after 12 months of storage. The formulation was active against all tested viruses. Cytotoxicity testing revealed minimal toxicity, with concentration-dependent inhibition of epithelial cell growth and stimulation of fibroblast proliferation. Discussion: EBBC exhibits strong and stable antiviral activity at low concentrations with minimal cytotoxic effects. Its unique combination of bee brood cap extract and enhanced marine plasma suggests potential for development as a natural, broad-spectrum antiviral formulation, offering an alternative to conventional antiviral agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.